Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bradley Pharmaceuticals

This article was originally published in The Tan Sheet

Executive Summary

Completes acquisition of approximately 68% of OTC manufacturer Doak Pharmacal for approximately $950,000 paid to Doak Chairman John Krafchuk and President Lorna Adams. A merger agreement for the remainder of Doak was approved by the existing board based upon the total purchase price of $1.4 mil. and will be considered by the new board, which will be named shortly. Also under the deal, Bradley Chairman and CEO Daniel Glassman will become chairman and president of Doak. Bradley announced the deal in October 1993 ("The Tan Sheet" Nov. 1, 1993, p. 7)
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS082471

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel